CymaBay Therapeutics (CBAY) Announces Oral Late-Breaking Presentation of Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With PBC at AASLD

October 20, 2016 2:42 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, today announced that a late-breaking presentation describing results from a phase 2 proof-of-concept study of MBX-8025 in patients with primary biliary cholangitis (PBC) will be delivered at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, November 11-15, 2016. MBX-8025 is an orally administered potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist.

The abstract, entitled “A phase 2 proof of concept study of MBX-8025 in patients with Primary Biliary Cholangitis (PBC) who are inadequate responders to ursodeoxycholic acid (UDCA)” is published on the AASLD website at The presentation will be made on November 15 by Professor David Jones, Professor of Liver Immunology, Institute of Cellular Medicine, Newcastle University in the U.K.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Related Entities


Add Your Comment